Universität zu Köln

Buettner, R. and Heydt, C. (2013). Biomarker analysis from a pathologist's view. Founding the rationale for personalised treatment of lung cancer. Bundesgesundheitsblatt-Gesund., 56 (11). S. 1502 - 1509. NEW YORK: SPRINGER. ISSN 1437-1588

Full text not available from this repository.

Abstract

The advent of genomic medicine and sequencing analysis of entire cancer genomes has rapidly improved our understanding of cancer genomics and has defined pathogenetic lesions initiating and driving cancer phenotypes in a causative manner. Moreover rapid development of small molecule inhibitors and highly selective biologicals provided effective tools to intervene with oncogenic signalling resulting from such lesions in the cancer genome. Thereby, the pathologist is now in the position to diagnose causative lesions in the cancer genome as molecular biomarkers directing the selection of patients for effective and highly selective therapies. If oncogenic driver lesions are vigorously validated preclinically and a useful diagnostic test is available, it is possible to provide a proof-of-concept at a very early stage of clinical drug development with the possibility of immediate personal benefit for participants in such phase I/II studies. This approach has significantly changed clinical testing and avoids testing proof for efficacy in large stage III clinical trials at a high failure rate. Therefore, our review summarises recent and paradigmatic progress in lung cancer biomarker diagnostics and defines academic and regulatory requirements for biomarker analysis and selective personalised therapies.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Buettner, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Heydt, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-472891
DOI:	10.1007/s00103-013-1823-1
Journal or Publication Title:	Bundesgesundheitsblatt-Gesund.
Volume:	56
Number:	11
Page Range:	S. 1502 - 1509
Date:	2013
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1437-1588
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ACQUIRED-RESISTANCE; IRREVERSIBLE INHIBITORS; KINASE INHIBITORS; DRUG-RESISTANCE; EGFR MUTATIONS; GEFITINIB; ERLOTINIB; RECEPTOR; T790M; ALK Multiple languages Public, Environmental & Occupational Health Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/47289